<DOC>
	<DOCNO>NCT02853929</DOCNO>
	<brief_summary>The purpose study assess immunogenicity safety Infanrix hexa booster dose give 12-18 month age infant receive primary vaccination 6-12 week . All infant booster study bear pregnant woman participate study 116945 [ DTPA ( BOOSTRIX ) -047 ] .</brief_summary>
	<brief_title>Evaluation Immunogenicity Safety Booster Dose Infanrix Hexa™ Healthy Infants Born Mothers Vaccinated With Boostrix™ During Pregnancy Immediately Post-delivery</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<criteria>Subjects ' parent ( ) /Legally acceptable representative ( LAR ( ) ) , opinion investigator , comply , requirement protocol ( e.g . completion diary card , return followup visit ) . Written inform consent obtain parent ( ) /LAR ( ) subject prior performing study specific procedure . A male female child 9 month age time enrolment . Healthy subject establish medical history clinical examination enter study . Subjects born mother vaccinate 116945 [ DTPA ( BOOSTRIX ) 047 ] study . Child care Concurrently participate another clinical study , within three month prior booster vaccine dose time present booster study , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug period within six month prior booster vaccine dose . For corticosteroid , mean prednisone ≥0.5mg/kg/day , equivalent . Inhaled topical steroid allow . Administration longacting immunemodifying drug time study period ( e.g . infliximab ) . A vaccine foreseen study protocol administer period start 30 day booster dose study vaccine end 30 day after* , exception inactivate influenza vaccine vaccine give part national/regional immunization schedule , allow time study period . In case emergency mass vaccination unforeseen public health threat ( e.g . : pandemic ) organise public health authority , outside routine immunization program , time period describe reduced necessary vaccine provide license use accord SPC Product Information ( PI ) accord local governmental recommendation provide write approval Sponsor obtain . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Major congenital defect . Serious chronic illness . Administration immunoglobulins and/or blood product period within three month booster dose study vaccine plan administration study period . Encephalopathy define acute , severe central nervous system disorder occur within 7 day follow vaccination Infanrix hexa generally consist major alteration consciousness , unresponsiveness , generalised focal seizure persist hour , failure recover within 24 hour . History Hib , diphtheria , tetanus , pertussis , pneumococcal , poliovirus hepatitis B diseases since conclusion visit study 201330 [ DTPA ( BOOSTRIX ) 048 PRI ] . Previous booster vaccination Hib , diphtheria , tetanus , pertussis , pneumococcus , hepatitis B and/or poliovirus since conclusion visit study 201330 [ DTPA ( BOOSTRIX ) 048 PRI ] . History reaction hypersensitivity likely exacerbate component vaccine ( e.g : antigen , excipients ) . Hypersensitivity latex . History neurological disorder seizure . Any condition judgment investigator would make intramuscular injection unsafe . Acute disease and/or fever time vaccination . Fever define temperature ≥ 37.5°C /99.5°F oral , axillary tympanic route , ≥ 38.0°C /100.4°F rectal route . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may enrol discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pertussis</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Diptheria</keyword>
</DOC>